Bridgeway Capital Management, LLC Otonomy, Inc. Transaction History

Bridgeway Capital Management, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$1.69 - $2.31 $689,858 - $942,942	-408,200 Reduced 55.79%	323,500 $673,000
Q3 2021 Nov 15, 2021	BUY	$1.22 - $2.2 $480,070 - $865,700	393,500 Added 116.35%	731,700 $1.41 Million
Q2 2021 Aug 16, 2021	BUY	$2.06 - $2.67 $294,374 - $381,543	142,900 Added 73.17%	338,200 $754,000
Q1 2021 May 17, 2021	BUY	$2.49 - $6.23 $204,180 - $510,860	82,000 Added 72.37%	195,300 $498,000
Q4 2020 Feb 16, 2021	SELL	$3.48 - $6.47 $163,560 - $304,090	-47,000 Reduced 29.32%	113,300 $733,000
Q1 2020 May 15, 2020	SELL	$1.58 - $4.06 $18,170 - $46,689	-11,500 Reduced 6.69%	160,300 $316,000
Q2 2019 Aug 14, 2019	SELL	$2.35 - $3.09 $33,605 - $44,187	-14,300 Reduced 7.68%	171,800 $472,000
Q1 2019 May 15, 2019	BUY	$1.8 - $2.97 $109,080 - $179,982	60,600 Added 48.29%	186,100 $489,000
Q4 2018 Feb 14, 2019	SELL	$1.51 - $2.93 $90,600 - $175,800	-60,000 Reduced 32.35%	125,500 $232,000
Q2 2018 Aug 14, 2018	BUY	$3.7 - $4.75 $686,350 - $881,125	185,500 New	185,500 $714,000

Ticker OTIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,990,400
Description
Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurot...

Get notified when there are updates to the investment portfolio of Bridgeway Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Bridgeway Capital Management, LLC with notifications on news.